Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Cyclin-Dependent Kinase 5 Dysfunction Contributes to Depressive-like Behaviors in Huntington's Disease by Altering the DARPP-32 Phosphorylation Status in the Nucleus Accumbens.

Brito V, Giralt A, Masana M, Royes A, Espina M, Sieiro E, Alberch J, Castañé A, Girault JA, Ginés S.

Biol Psychiatry. 2019 Mar 13. pii: S0006-3223(19)30151-9. doi: 10.1016/j.biopsych.2019.03.001. [Epub ahead of print]

PMID:
31060804
2.

Dopaminergic and glutamatergic signaling crosstalk in Huntington's disease neurodegeneration: the role of p25/cyclin-dependent kinase 5.

Paoletti P, Vila I, Rifé M, Lizcano JM, Alberch J, Ginés S.

J Neurosci. 2008 Oct 1;28(40):10090-101. doi: 10.1523/JNEUROSCI.3237-08.2008.

3.

Acute drug-induced spine changes in the nucleus accumbens are dependent on β-adducin.

Engmann O, Giralt A, Girault JA.

Neuropharmacology. 2016 Nov;110(Pt A):333-342. doi: 10.1016/j.neuropharm.2016.07.035. Epub 2016 Jul 29.

PMID:
27480796
4.
5.
6.

Cdk5 Contributes to Huntington's Disease Learning and Memory Deficits via Modulation of Brain Region-Specific Substrates.

Alvarez-Periel E, Puigdellívol M, Brito V, Plattner F, Bibb JA, Alberch J, Ginés S.

Mol Neurobiol. 2018 Aug;55(8):6250-6268. doi: 10.1007/s12035-017-0828-4. Epub 2017 Dec 29.

PMID:
29288339
7.

Cyclin-dependent kinase 5 in the ventral tegmental area regulates depression-related behaviors.

Zhong P, Liu X, Zhang Z, Hu Y, Liu SJ, Lezama-Ruiz M, Joksimovic M, Liu QS.

J Neurosci. 2014 Apr 30;34(18):6352-66. doi: 10.1523/JNEUROSCI.3673-13.2014.

8.

The Cdk5 inhibitor Roscovitine increases LTP induction in corticostriatal synapses.

Miranda-Barrientos J, Nieto-Mendoza E, Hernández-Echeagaray E.

ASN Neuro. 2014 Mar 19;6(2). pii: e00140. doi: 10.1042/AN20140006.

9.

Differential proteomic and genomic profiling of mouse striatal cell model of Huntington's disease and control; probable implications to the disease biology.

Choudhury KR, Das S, Bhattacharyya NP.

J Proteomics. 2016 Jan 30;132:155-66. doi: 10.1016/j.jprot.2015.11.007. Epub 2015 Nov 12.

PMID:
26581643
10.

Muscarinic acetylcholine M4 receptors play a critical role in oxotremorine-induced DARPP-32 phosphorylation at threonine 75 in isolated medium spiny neurons.

Liu L, Huang Y, Huang Q, Zhao Z, Yu J, Wang L.

Neuropharmacology. 2017 May 1;117:376-386. doi: 10.1016/j.neuropharm.2017.02.026. Epub 2017 Mar 1.

PMID:
28257887
11.

DARPP-32 interaction with adducin may mediate rapid environmental effects on striatal neurons.

Engmann O, Giralt A, Gervasi N, Marion-Poll L, Gasmi L, Filhol O, Picciotto MR, Gilligan D, Greengard P, Nairn AC, Hervé D, Girault JA.

Nat Commun. 2015 Dec 7;6:10099. doi: 10.1038/ncomms10099.

12.

Loss of Cdk5 function in the nucleus accumbens decreases wheel running and may mediate age-related declines in voluntary physical activity.

Ruegsegger GN, Toedebusch RG, Childs TE, Grigsby KB, Booth FW.

J Physiol. 2017 Jan 1;595(1):363-384. doi: 10.1113/JP272489. Epub 2016 Sep 15.

13.

MicroRNA-124 targets CCNA2 and regulates cell cycle in STHdh(Q111)/Hdh(Q111) cells.

Das E, Jana NR, Bhattacharyya NP.

Biochem Biophys Res Commun. 2013 Jul 26;437(2):217-24. doi: 10.1016/j.bbrc.2013.06.041. Epub 2013 Jun 21.

PMID:
23796713
14.

Locomotor conditioning by amphetamine requires cyclin-dependent kinase 5 signaling in the nucleus accumbens.

Singer BF, Neugebauer NM, Forneris J, Rodvelt KR, Li D, Bubula N, Vezina P.

Neuropharmacology. 2014 Oct;85:243-52. doi: 10.1016/j.neuropharm.2014.05.033. Epub 2014 Jun 2.

15.

The p75 neurotrophin receptor augments survival signaling in the striatum of pre-symptomatic Q175(WT/HD) mice.

Wehner AB, Milen AM, Albin RL, Pierchala BA.

Neuroscience. 2016 Jun 2;324:297-306. doi: 10.1016/j.neuroscience.2016.02.069. Epub 2016 Mar 3.

16.

Dopamine signaling negatively regulates striatal phosphorylation of Cdk5 at tyrosine 15 in mice.

Yamamura Y, Morigaki R, Kasahara J, Yokoyama H, Tanabe A, Okita S, Koizumi H, Nagahiro S, Kaji R, Goto S.

Front Cell Neurosci. 2013 Feb 14;7:12. doi: 10.3389/fncel.2013.00012. eCollection 2013.

17.

A novel tyrosine kinase inhibitor AMN107 (nilotinib) normalizes striatal motor behaviors in a mouse model of Parkinson's disease.

Tanabe A, Yamamura Y, Kasahara J, Morigaki R, Kaji R, Goto S.

Front Cell Neurosci. 2014 Feb 20;8:50. doi: 10.3389/fncel.2014.00050. eCollection 2014.

18.

Hippocampal glycogen synthase kinase 3β is critical for the antidepressant effect of cyclin-dependent kinase 5 inhibitor in rats.

Li G, Liu T, Kong X, Wang L, Jin X.

J Mol Neurosci. 2014 Sep;54(1):92-9. doi: 10.1007/s12031-014-0254-2. Epub 2014 Feb 22.

PMID:
24563226
19.

AKT and CDK5/p35 mediate brain-derived neurotrophic factor induction of DARPP-32 in medium size spiny neurons in vitro.

Bogush A, Pedrini S, Pelta-Heller J, Chan T, Yang Q, Mao Z, Sluzas E, Gieringer T, Ehrlich ME.

J Biol Chem. 2007 Mar 9;282(10):7352-9. Epub 2007 Jan 5.

20.

Cyclin-dependent kinase 5 regulates dopaminergic and glutamatergic transmission in the striatum.

Chergui K, Svenningsson P, Greengard P.

Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):2191-6. Epub 2004 Feb 9.

Supplemental Content

Support Center